Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct;7(1):30-37.

A Survey on the Role of Interleukin-10 in Breast Cancer: A Narrative

Elnaz Sheikhpour  1 , Parisa Noorbakhsh  2 , Elnaz Foroughi  3 , Soudabeh Farahnak  4 , Rezvan Nasiri  5 , Hossein Neamatzadeh  6
Affiliations

A Survey on the Role of Interleukin-10 in Breast Cancer: A Narrative

Elnaz Sheikhpour et al. Rep Biochem Mol Biol. 2018 Oct.

Abstract

Interleukin (IL)-10, a multifunctional immune-regulatory cytokine with both immunosuppressive and anti-angiogenic functions, is produced by immune cells including macrophages, T lymphocytes, and natural killer cells. Among other effects, IL-10 promotes tumor cell proliferation and metastasis via immunosuppression. Interleukin-10-mediated immunosuppression is aided by synthesis of tumor necrosis factor, IL-1, IL-12, and chemokines, and down regulation of the surface co-stimulatory molecules CD80 and CD86 on tumors. Interleukin-10 also promotes IL-6 expression and synthesis, which causes cell proliferation via B cell lymphoma-2 (Bcl-2) upregulation and changes the proliferation/apoptosis equivalence toward neoplastic cell proliferation. Moreover, IL-10 inhibits tumorigenesis via down-regulation of VEGF, IL-1b, TNF-α, IL-6, and MMP-9. Interleukin-10 also inhibits nuclear factor-KB (NF-KB) translocation. Interleukin-10 has been reported to have both tumor-promoting and -inhibiting properties. It seems that IL-10 agonists and antagonists may have therapeutic effects via different mechanisms. Moreover, IL-10 gene polymorphisms may determine breast cancer susceptibility.

Keywords: Breast cancer; Cytokine; IL-10.

PubMed Disclaimer

References

    1. Sheikhpour R. Evaluation of Tp53 codon 72 polymorphism and resulted protein in breast cancer patients in Yazd city. Iran J Breast Dis. 2014;7(3):20–29.
    1. Forat-Yazdi M, Rafieian S, Gholi-Nataj M, Sheikhha MH, Nazari T, Neamatzadeh H. CYP2D6 genotype and risk of recurrence in tamoxifen treated breast cancer patients. Asian Pac J Cancer Prev. 2015;16(15):6783–7. - PubMed
    1. Sheikhpour R, Mohiti J. The effect of progesterone on p53 in T47D cell line. Urmia J Med Sci. 2014;25(10):954–960.
    1. Sabe M, Nehs M, Gang S, Lowler S, Ferrara J, Chang A. Immunologic approaches to breast cancer treatment. Surg Oncol Clin N Am. 2005;90(1):97–104. - PubMed
    1. Khan H, Changkija B, Konwar R. Role of Interleukin-10 in Breast Cancer. Breast Cancer Res Treat. 2012;133(1):11–21. - PubMed

LinkOut - more resources